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To the Editor: Excess levels of TNF-α have been associ-
ated with certain autoimmune diseases. Prolonged admin-
istration of TNF-α antibody is used to effectively treat
chronic inflammatory diseases such as rheumatic diseases
and Crohn’s disease [1]. Anti-TNF-α drugs have clearly
been shown to suppress disease activity in rheumatoid
arthritis, and are a candidate therapy for immune interven-
tion in type 1 diabetes. We report a case of a patient with
juvenile idiopathic arthritis, who developed type 1 diabetes
while receiving anti-TNF-α therapy.
Case history and examination
A 35-year-old woman (HLA-DR3-DQ2 homozygous) was
diagnosed with juvenile idiopathic arthritis (rheumatoid
factor-positive) at 15 years of age. Her mother had been
diagnosed with type 1 diabetes at 29 years of age. Over the
years, the disease appeared to be largely resistant to
therapy; despite treatment with sulfasalazine, auranofin,
hydroxychloroquine, methotrexate, azathioprine, penicilla-
mine, prednisone and ciclosporin consecutively, she devel-
oped severe joint destruction for which she received several
joint replacements, including both shoulders and knees. In
1997, she participated in a trial on TNF-α antibody therapy
(adalimumab) for approximately half a year, without clear
benefit. In 1999, she received five cyclophosphamide
infusions, which had only a partial, temporary effect. The
only approach that suppressed her arthritis was the regular
injection of methylprednisolone. At the end of 2000, she
was started on etanercept, a subcutaneously administered
TNF-α antagonist, at a dose of 25 mg, twice a week. This
treatment had a clear beneficial effect on her arthritis. Her
28 joint disease activity score (DAS28), a validated
composite score [2], substantially decreased. Methylpred-
nisolone administration was successfully tapered before
finally being completely discontinued, and she needed
fewer non-steroidal anti-inflammatory drugs. In 2000 and
2001, measured plasma glucose levels (non-fasting) were
5.7 and 6.1 mmol/l. The patient continued to report a
beneficial effect of etanercept treatment, although the
therapy did not completely suppress her joint inflammation.
In 2003, she noticed polydipsia and polyuria, genital
candida, generalised fatigue and a 3 kg loss of body weight.
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Nijmegen, the NetherlandsHer blood glucose level was >25 mmol/l, and her HbA1c
was 11.6% (reference value 4.8–6.1%). The level of GAD
autoantibody (GADA), determined by ELISA (RSR,
Cardiff, UK), was very high at 1,312 U/ml (normal value
<5 U/ml). The patient was put on multiple daily insulin
injections (combination insulin aspart and insulin glargine),
which resulted in the rapid relief of symptoms, normal-
isation of blood glucose levels and HbA1c, and an increase
in weight. The patient currently requires a daily dose of
insulin of ~0.75 U/kg.
To determine whether the appearance of GADA
preceded etanercept therapy, earlier samples were
screened for this antibody. Retrospective serology
revealed the presence of GADA in 1997, prior to the
patient’s participation in the adalimumab trial. During
the course of TNF-α antibody administration, the
GADA titres rose tenfold, to exceptionally high titres
(Fig. 1). IA-2 autoantibodies were not detectable at any
time point.
Conclusions
Our case report illustrates important points concerning the
effect of anti-TNF-α therapy in the context of the
development of type 1 diabetes. First, we confirm a clear
beneficial effect of anti-TNF-α therapy on rheumatoid
arthritis. Second, anti-TNF-α therapy did not prevent the
development or the progression of type 1 diabetes.
Evidence has accumulated from clinical trials that
anti-TNF-α therapies can, under certain circumstances,
promote rather than quell certain forms of autoimmunity
[3]. In rheumatoid arthritis, therapy with diverse thera-
peutic forms of TNF-α antagonists is associated with
relatively common and detectable autoimmune adverse
events, such as multiple sclerosis, lupus and diabetes [1].
Prior to the present report, a case of type 1 diabetes was
reported in a 7-year-old girl undergoing treatment for
juvenile rheumatoid arthritis with a TNF-α antagonist
(etanercept) [4].
There are indications that TNF-α may play a dual role in
type 1 diabetes. Studies on animal models of type 1
diabetes have shown that TNF-α suppression is essential
for progression to autoimmune diabetes. Anti-TNF-α
appears to have a rather narrow therapeutic window in
NOD mice. Anti-TNF-α treatment before 3 weeks of
age induced immunological tolerance to islet cell
proteins, while administration of anti-TNF-α treatment
at 4 weeks of age or later resulted in the accelerated
development of diabetes, producing an increased inci-
dence [5]. Although we appreciate the limitations of
animal studies [6], these reports demonstrate that TNF-α
can serve as a double-edged sword in autoimmune
diabetes by positively or negatively regulating peripheral
T cell tolerance to beta cell antigens.
In patients with rheumatoid arthritis, anti-TNF-α therapy
has been found to improve the suppressive abilities of
regulatory T cells [7]. Although this feature could benefit
type 1 diabetic patients in whom regulatory T cell function
has been shown to be impaired [8], it was not found to do
so in the case reported here.
We propose that the use of anti-TNF-α therapies such as
etanercept appears to be ineffective for the prevention of
type 1 diabetes. Although there is currently no evidence
that such a therapy precipitates type 1 diabetes, this
possibility cannot be ruled out, and care should be taken
in extrapolating the beneficial effects of anti-TNF-α
therapies in other autoimmune diseases to their application
in type 1 diabetes.
0
50,000
100,000
150,000
0
2
4
6
G
A
D
A
(
U
/
m
l
)
D
A
S
2
8
1997 1998 1999 2000 2001 2002 2004 2003
Etanercept
Cyclophosphamide
Methylprednisone
Adalimumab
Type 1 diabetes
Year
Fig. 1 Time course of findings. The y-axis on the left indicates the
level of GADA (data shown as bars). The y-axis on the right indicates
the DAS28 score (data shown as a solid line); a score of <3.2 reflects
low disease activity; a score of 3.2–5.1 reflects moderate disease
activity and a score of >5.1 reflects high disease activity. The bar
indicating methylprednisone is lighter on the right-hand side to denote
tapering of the treatment
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